ICU Medical Reports Q4 2025 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Source: seekingalpha
- Revenue Growth: ICU Medical reported Q4 2025 revenue of $536 million, reflecting a 14% decline in reported terms but achieving 2% organic growth, with a full-year organic growth of 5%, indicating the company's stability and growth potential in the market.
- Cost and Profit Analysis: The adjusted gross margin stood at 40.5%, aligning with prior guidance, while adjusted EBITDA was $98 million, a 7% decrease year-over-year primarily due to the deconsolidation of IV Solutions and tariffs, highlighting challenges in cost control.
- Future Outlook: The company anticipates organic revenue growth in the low to mid-single-digit range for 2026, with an adjusted EBITDA target of $400 million to $430 million, reflecting management's confidence in future growth and market demand.
- Strategic Integration Progress: Management emphasized the completion of several integration milestones, including the closure of the FDA warning letter, which is expected to provide more strategic options for the company and further drive innovation and operational synergies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICUI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICUI
Wall Street analysts forecast ICUI stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 140.370
Low
172.00
Averages
173.50
High
175.00
Current: 140.370
Low
172.00
Averages
173.50
High
175.00
About ICUI
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume intravenous (IV) pumps and safety software, dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions. Its product offerings also include Consumables, Infusion Systems and Vital Care. Its consumables business unit includes infusion therapy, oncology, vascular access, and tracheostomy products. Its infusion systems offer a portfolio of infusion pumps, software, and professional services. Its vital care business unit includes hemodynamic monitoring, general anesthesia and respiratory, temperature management solutions and regional anesthesia/pain management products. Its infusion therapy products include infusion sets, extension sets, needle-free connectors, and disinfection caps.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Ratings Overview
- Morgan Stanley Bullish on Onto Innovation: Morgan Stanley initiates Onto Innovation with an overweight rating, citing potential upside to consensus estimates driven by its process control capabilities in both front-end and back-end operations, suggesting a favorable re-rating ahead.
- Needham Initiates Ceva as Buy: Needham launches coverage of Ceva with a Buy rating and a price target of $55, indicating a 70x P/E based on CY27 EPS estimates, as the company is positioned to benefit from AI advancements in the semiconductor sector.
- UBS Initiates Jade Biosciences as Buy: UBS rates Jade Biosciences as a Buy, highlighting its best-in-class potential, with expectations that the FDA's acceptance of shorter eGFR kidney function data will expedite enrollment in pivotal studies.
- Morgan Stanley Upgrades Ferrari: Morgan Stanley upgrades Ferrari to overweight from equal weight, raising the price target to $438, arguing that the current de-rating overstates brand risk and that the company’s wealth creation and product pipeline support a positive re-rating.
See More
ICU Medical VP Sells Shares Worth $304,000
- Share Sale Details: Virginia Ruth Sanzone, VP and General Counsel of ICU Medical, sold 2,447 shares on May 14, 2026, for approximately $304,000, representing 11.17% of her direct holdings, indicating potential liquidity concerns.
- Market Performance Insight: The sale occurred at a price of $124.08 per share, while the post-transaction market close was $122.99, reflecting short-term volatility that could impact investor confidence in ICU Medical's stock.
- Financial Condition Consideration: With around $1 billion in net debt from the Smiths Medical acquisition, ICU Medical's management aims for a 43% gross margin exit rate, yet high debt levels combined with the current interest rate environment may pressure future buyback plans.
- Industry Competition and Outlook: ICU Medical focuses on infusion therapy infrastructure, and while its consumables model provides stable revenue, investors must carefully assess the company's execution capabilities and market outlook in a challenging macroeconomic environment.
See More
ICU Medical Executive Sells Shares, Impact on Holdings
- Transaction Overview: Virginia Ruth Sanzone, Vice President and General Counsel at ICU Medical, sold 2,447 shares on May 14, 2026, for approximately $304,000, marking her largest single direct sale in the past year, surpassing previous sales of 700 and 930 shares.
- Change in Holdings: This sale reduced Sanzone's direct holdings from 21,907 to 19,460 shares, accounting for 11.17% of her available shares, consistent with her historical pattern of periodic net selling, indicating a cautious market outlook.
- Price Analysis: The shares were sold at $124.08 each, slightly above the market close of $122.99 on May 14, 2026; however, by May 17, 2026, the stock price had dropped to $118.72, reflecting a one-year total return of -16.03%.
- Company Financial Snapshot: ICU Medical reported a trailing twelve-month revenue of $2.16 billion and a net income of $46.34 million, with 15,000 employees; despite a 4.2% increase in stock price over the past year, the company faces approximately $1 billion in net debt from the 2022 Smiths Medical acquisition, raising concerns about future profitability and growth potential.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
ICU Medical Q1 2026 Earnings Call Insights
- Slow Revenue Growth: ICU Medical reported revenue of $526 million for Q1 2026, reflecting a 1% organic growth but a 12% decline in reported figures, indicating weak market demand that could impact future investment confidence.
- Margin Improvement: The adjusted gross margin for the first quarter was 41%, slightly exceeding expectations due to a favorable product mix in infusion businesses, which enhances the company's profitability in a competitive medical device market.
- Free Cash Flow Performance: The company generated $28 million in free cash flow during the first quarter, despite recognizing $10 million in tariff expenses, demonstrating effective cash flow management that supports future debt reduction and capital returns.
- Stable Market Outlook: Management reiterated that the full-year financial guidance remains applicable, estimating that a $10 increase in oil prices would result in an additional $3 million in annual expenses, highlighting the company's sensitivity to external economic factors and its strategic response.
See More
ICU Medical Announces Q1 2026 Earnings Release Schedule
- Earnings Release Schedule: ICU Medical will release its Q1 2026 earnings on May 7, 2026, at 4:00 p.m. ET, reflecting the company's ongoing innovation and development in the medical products sector.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 4:30 p.m. ET on the same day, providing investors and analysts with an in-depth analysis of the financial results, enhancing transparency and communication.
- Webcast Availability: The conference call will be accessible via webcast, allowing investors to easily access the information through the company's website, ensuring widespread dissemination and timely access to critical updates.
- Company Background: ICU Medical is a global leader in infusion systems and high-value critical care products, committed to delivering quality and innovative medical solutions to clinical customers worldwide, further solidifying its market position.
See More
Latest Wall Street Ratings Overview
- Morgan Stanley Bullish on Onto Innovation: Morgan Stanley initiates Onto Innovation with an overweight rating, citing potential upside to consensus estimates driven by its process control capabilities in both front-end and back-end operations, suggesting a favorable re-rating ahead.
- Needham Initiates Ceva as Buy: Needham launches coverage of Ceva with a Buy rating and a price target of $55, indicating a 70x P/E based on CY27 EPS estimates, as the company is positioned to benefit from AI advancements in the semiconductor sector.
- UBS Initiates Jade Biosciences as Buy: UBS rates Jade Biosciences as a Buy, highlighting its best-in-class potential, with expectations that the FDA's acceptance of shorter eGFR kidney function data will expedite enrollment in pivotal studies.
- Morgan Stanley Upgrades Ferrari: Morgan Stanley upgrades Ferrari to overweight from equal weight, raising the price target to $438, arguing that the current de-rating overstates brand risk and that the company’s wealth creation and product pipeline support a positive re-rating.
See More
ICU Medical VP Sells Shares Worth $304,000
- Share Sale Details: Virginia Ruth Sanzone, VP and General Counsel of ICU Medical, sold 2,447 shares on May 14, 2026, for approximately $304,000, representing 11.17% of her direct holdings, indicating potential liquidity concerns.
- Market Performance Insight: The sale occurred at a price of $124.08 per share, while the post-transaction market close was $122.99, reflecting short-term volatility that could impact investor confidence in ICU Medical's stock.
- Financial Condition Consideration: With around $1 billion in net debt from the Smiths Medical acquisition, ICU Medical's management aims for a 43% gross margin exit rate, yet high debt levels combined with the current interest rate environment may pressure future buyback plans.
- Industry Competition and Outlook: ICU Medical focuses on infusion therapy infrastructure, and while its consumables model provides stable revenue, investors must carefully assess the company's execution capabilities and market outlook in a challenging macroeconomic environment.
See More
ICU Medical Executive Sells Shares, Impact on Holdings
- Transaction Overview: Virginia Ruth Sanzone, Vice President and General Counsel at ICU Medical, sold 2,447 shares on May 14, 2026, for approximately $304,000, marking her largest single direct sale in the past year, surpassing previous sales of 700 and 930 shares.
- Change in Holdings: This sale reduced Sanzone's direct holdings from 21,907 to 19,460 shares, accounting for 11.17% of her available shares, consistent with her historical pattern of periodic net selling, indicating a cautious market outlook.
- Price Analysis: The shares were sold at $124.08 each, slightly above the market close of $122.99 on May 14, 2026; however, by May 17, 2026, the stock price had dropped to $118.72, reflecting a one-year total return of -16.03%.
- Company Financial Snapshot: ICU Medical reported a trailing twelve-month revenue of $2.16 billion and a net income of $46.34 million, with 15,000 employees; despite a 4.2% increase in stock price over the past year, the company faces approximately $1 billion in net debt from the 2022 Smiths Medical acquisition, raising concerns about future profitability and growth potential.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
ICU Medical Q1 2026 Earnings Call Insights
- Slow Revenue Growth: ICU Medical reported revenue of $526 million for Q1 2026, reflecting a 1% organic growth but a 12% decline in reported figures, indicating weak market demand that could impact future investment confidence.
- Margin Improvement: The adjusted gross margin for the first quarter was 41%, slightly exceeding expectations due to a favorable product mix in infusion businesses, which enhances the company's profitability in a competitive medical device market.
- Free Cash Flow Performance: The company generated $28 million in free cash flow during the first quarter, despite recognizing $10 million in tariff expenses, demonstrating effective cash flow management that supports future debt reduction and capital returns.
- Stable Market Outlook: Management reiterated that the full-year financial guidance remains applicable, estimating that a $10 increase in oil prices would result in an additional $3 million in annual expenses, highlighting the company's sensitivity to external economic factors and its strategic response.
See More
ICU Medical Announces Q1 2026 Earnings Release Schedule
- Earnings Release Schedule: ICU Medical will release its Q1 2026 earnings on May 7, 2026, at 4:00 p.m. ET, reflecting the company's ongoing innovation and development in the medical products sector.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 4:30 p.m. ET on the same day, providing investors and analysts with an in-depth analysis of the financial results, enhancing transparency and communication.
- Webcast Availability: The conference call will be accessible via webcast, allowing investors to easily access the information through the company's website, ensuring widespread dissemination and timely access to critical updates.
- Company Background: ICU Medical is a global leader in infusion systems and high-value critical care products, committed to delivering quality and innovative medical solutions to clinical customers worldwide, further solidifying its market position.
See More
